Biogen Inc
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty Images Sales of the Alzheimer’s drug Leqembi may be slow initially due to logistical requirements but could pick […]
Read More
Stocks producing the largest moves midday: Rivian, Levi Strauss, Biogen, To start with Photo voltaic and additional
In this posting META DKNG FSLR BABA Observe your favored sharesGenerate Absolutely free ACCOUNT A Rivian emblem on an Amazon.com supply electric van photographed in Chicago, Illinois, on July 21, 2022. Jamie Kelter Davis | Bloomberg | Getty Photographs Test out the companies generating headlines in midday trading. Alibaba — U.S. shares of the Chinese […]
Read More
Shares creating the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more
In this write-up BE BABA BIIB LEVI Adhere to your beloved sharesMake Free of charge ACCOUNT The Levi Strauss & Co. label is observed on denims in a retail store at the Woodbury Popular Premium Retailers in Central Valley, New York, U.S., February 15, 2022. Andrew Kelly | Reuters Test out the firms creating the […]
Read More
Japanese pharma Eisai slides 4% even with Fda approval for Alzheimer’s drug
Signage for Eisai Co. at the company’s headquarters in Tokyo, Japan, on Friday, Feb. 3, 2023. Bloomberg | Bloomberg | Getty Visuals Shares of Japanese pharmaceutical huge Eisai sank Friday following the company’s Alzheimer’s drug was formally accredited by U.S. regulators overnight, prompting queries about trader sentiment surrounding the shift. Tokyo-outlined shares of Eisai fell […]
Read More
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
The Food and Drug Administration on Thursday approved the Alzheimer’s treatment Leqembi, a pivotal decision that is expected to expand access to the expensive drug for older Americans. Medicare has promised to start covering Leqembi, with some conditions, on the same day the FDA approves the antibody treatment. Leqembi is made by Japanese pharmaceutical company […]
Read More
Shares generating the largest moves midday: JD.com, Biogen, Oracle and a lot more
A JD.com truck obtaining incoming items and getting ready shipments at the Northeast China-primarily based Gu’an warehouse and distribution facility in Gu’an, Сhina. XiXinXing | iStock Editorial | Getty Photos Examine out the corporations producing headlines in midday buying and selling. Biogen — Shares of the biotech inventory dipped 3% just after Biogen revamped its […]
Read More
FDA advisors weigh whether Alzheimer’s drug Leqembi should receive full approval
[The stream is scheduled to begin at 10 a.m. ET. Please refresh the page if you don’t see a player above at that time.] A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer’s drug Leqembi, made by Eisai and Biogen, should receive […]
Read More
Bernie Sanders says price of Alzheimer’s treatment is unconscionable, calls on HHS to take action
Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC. Anna Moneymaker | Getty Images Sen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to ensure seniors can actually afford the expensive Alzheimer’s treatment Leqembi. Sanders, who chairs the Senate […]
Read More
Oppenheimer says investors are missing opportunities in three biotech areas and the related stocks
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. “Our analysis shows Genetic Medicine and Metabolic […]
Read More
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | Reuters The new Alzheimer’s antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research published in a leading medical journal this week. Medicare would spend about $2 billion per year […]
Read More